X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dishman Pharma with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ACTAVIS (US) - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DISHMAN PHARMA   ACTAVIS
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ACTAVIS
Dec-14
DISHMAN PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs37419,396-   
Low Rs12911,831-   
Sales per share (Unadj.) Rs197.83,492.7-  
Earnings per share (Unadj.) Rs21.2-435.9-  
Cash flow per share (Unadj.) Rs34.7320.4-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.97,575.5-  
Shares outstanding (eoy) m80.69265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.5 28.5%   
Avg P/E ratio x11.9-35.8 -33.1%  
P/CF ratio (eoy) x7.248.7 14.9%  
Price / Book Value ratio x1.42.1 67.9%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,3064,151,646 0.5%   
No. of employees `0000.821.6 3.8%   
Total wages/salary Rs m5,3550-   
Avg. sales/employee Rs Th19,252.742,995.8 44.8%   
Avg. wages/employee Rs Th6,459.50-   
Avg. net profit/employee Rs Th2,064.1-5,365.4 -38.5%   
INCOME DATA
Net Sales Rs m15,961928,708 1.7%  
Other income Rs m265-2,318 -11.5%   
Total revenues Rs m16,226926,390 1.8%   
Gross profit Rs m4,103119,306 3.4%  
Depreciation Rs m1,091201,099 0.5%   
Interest Rs m94429,293 3.2%   
Profit before tax Rs m2,334-113,405 -2.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0-8,319 0.0%   
Tax Rs m624-5,830 -10.7%   
Profit after tax Rs m1,711-115,893 -1.5%  
Gross profit margin %25.712.8 200.1%  
Effective tax rate %26.75.1 519.8%   
Net profit margin %10.7-12.5 -85.9%  
BALANCE SHEET DATA
Current assets Rs m11,018489,310 2.3%   
Current liabilities Rs m9,517356,851 2.7%   
Net working cap to sales %9.414.3 65.9%  
Current ratio x1.21.4 84.4%  
Inventory Days Days11058 190.5%  
Debtors Days Days3566 52.6%  
Net fixed assets Rs m16,304113,405 14.4%   
Share capital Rs m1610-   
"Free" reserves Rs m12,9070-   
Net worth Rs m14,5162,014,334 0.7%   
Long term debt Rs m4,1891,055,551 0.4%   
Total assets Rs m29,8053,691,612 0.8%  
Interest coverage x3.5-2.9 -120.9%   
Debt to equity ratio x0.30.5 55.1%  
Sales to assets ratio x0.50.3 212.9%   
Return on assets %8.9-2.3 -379.8%  
Return on equity %11.8-5.8 -204.9%  
Return on capital %17.5-3.0 -582.2%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Net fx Rs m4,2550-   
CASH FLOW
From Operations Rs m2,786159,477 1.7%  
From Investments Rs m-1,529-381,850 0.4%  
From Financial Activity Rs m-941214,544 -0.4%  
Net Cashflow Rs m316-7,828 -4.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 71.1 Rs / USD

Compare DISHMAN PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare DISHMAN PHARMA With: LUPIN LTD  FULFORD INDIA  CADILA HEALTHCARE  J.B.CHEMICALS  PFIZER  



Today's Market

Recapitalisation Package for PSBs: The Pros & Cons(Podcast)

Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.

Related Views On News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

Eris Lifesciences Limited (IPO)

Jun 15, 2017

Exposure to high margin specialty products offers promising growth prospects.

More Views on News

Most Popular

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

The 4-Point Plan to Accelerate India to a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Feb 12, 2019

Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.

The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)

Feb 15, 2019

Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - FDC LTD. COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS